MedTrace Logo

Ablation in Brugada Syndrome for the Prevention of VF

NCT02704416 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-11-21

No results posted yet for this study

Summary

This trial aims to develop evidence based curative treatment with optimal net benefit for patients with Brugada syndrome.

Conditions

  • Brugada Syndrome

Interventions

PROCEDURE

Catheter Ablation

catheter ablation of fragmented signal in the right ventricular outflow tract

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Pacific Rim Electrophysiology Research Institute

    lead OTHER

Principal Investigators

  • Koonlawee Nademanee, MD · Pacific Rim Electrophysiology Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2024-11-13
Completion
2024-11-13

Countries

  • Netherlands
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704416 on ClinicalTrials.gov